By multivariable logistic analysis, TSG-6 remained an independent relevant factor for the functional outcome, which suggested that plasma TSG-6 level might be an emerging predictor of short-term prognosis in non-cardioembolic AIS and could help to screen for high-risk patients who need aggressive monitoring and treatment. The gene discussed is TNFAIP6; the disease is androgen insensitivity syndrome.